NAVLE Gastrointestinal and Digestive

Canine Exocrine Pancreatic Tumor Study Guide

📅 March 28, 2026 ⏱ 25 min read 👁 1 views

Exocrine pancreatic tumors represent a rare but highly aggressive group of neoplasms arising from the exocrine (acinar or ductal) cells of the pancreas.

Overview and Clinical Importance

Exocrine pancreatic tumors represent a rare but highly aggressive group of neoplasms arising from the exocrine (acinar or ductal) cells of the pancreas. Unlike the more commonly discussed insulinomas, which originate from the endocrine pancreas, exocrine pancreatic adenocarcinomas account for the majority of malignant exocrine pancreatic neoplasms in dogs. These tumors are characterized by their late clinical presentation, high metastatic rate (approximately 78% at diagnosis), and grave prognosis. Understanding the pathophysiology, diagnosis, and limited treatment options is essential for NAVLE success and clinical practice.

The canine pancreas is a V-shaped gland located in the cranial abdomen with both exocrine and endocrine functions. The exocrine portion comprises approximately 95% of the pancreatic parenchyma and is responsible for producing digestive enzymes, while the endocrine portion (Islets of Langerhans) produces insulin and glucagon. Exocrine pancreatic tumors arise from either the acinar cells (which produce digestive enzymes) or the ductal epithelium.

Tumor Type	Cell of Origin	Behavior
Pancreatic Adenoma	Acinar or ductal cells	Benign; rare; usually incidental finding
Acinar Adenocarcinoma	Acinar cells (enzyme-producing)	Malignant; MOST COMMON in dogs (greater than 85% of exocrine tumors)
Ductal Adenocarcinoma	Ductal epithelial cells	Malignant; less common in dogs (more common in humans)

Anatomy and Pathophysiology

Normal Pancreatic Anatomy

The canine pancreas is a compound tubuloalveolar gland consisting of a right lobe (following the descending duodenum), left lobe (embedded in the deep leaf of the greater omentum near the stomach), and a body that connects the two lobes near the pylorus. The right lobe is larger and extends from the ninth intercostal space to approximately the fourth lumbar vertebra.

Key Anatomical Points

Ductal System: In dogs, the accessory pancreatic duct (duct of Santorini) is typically the main functional duct, opening at the minor duodenal papilla. The pancreatic duct (duct of Wirsung) opens at the major duodenal papilla alongside the common bile duct.
Blood Supply: Supplied by pancreatic branches of the splenic artery and the superior and inferior pancreaticoduodenal arteries.
Lymphatic Drainage: To pancreaticosplenic and pyloric nodes, then to superior mesenteric and celiac lymph nodes.

Classification of Exocrine Pancreatic Tumors

Exocrine pancreatic tumors are classified based on their cell of origin and biological behavior:

High-YieldUnlike humans where ductal adenocarcinoma predominates (90% of pancreatic cancers), dogs more commonly develop ACINAR adenocarcinoma. This is an important species difference to remember for NAVLE. Additionally, canine pancreatic acinar carcinomas lack the KRAS mutations commonly found in human ductal adenocarcinomas, which has implications for treatment response.

Factor	Details
Age	Middle-aged to older dogs (median age 9-11 years)
Sex Predisposition	Older female dogs appear at higher risk in some studies
Breed Predisposition	Labrador Retrievers, Airedale Terriers, Boxers, and Spaniel breeds
Location	Right lobe most common (47%), followed by left lobe (33%), then body (20%)
Metastasis at Diagnosis	Approximately 78% have metastatic disease at time of diagnosis

Epidemiology and Risk Factors

Incidence and Demographics

Exocrine pancreatic carcinoma is rare in dogs, representing less than 0.5% of all canine cancers. Despite the rarity, understanding this tumor is critical due to its aggressive nature and the poor prognosis associated with diagnosis.

Board Tip - LABS Memory Aid: Breeds at risk for pancreatic adenocarcinoma = LABS: Labrador retrievers, Airedales, Boxers, Spaniels. Remember: LABS get Labs (laboratory tests) done for pancreatic tumors!

Clinical Sign	Frequency	Mechanism
Anorexia	Very common	Paraneoplastic syndrome, nausea, abdominal discomfort
Weight Loss	Very common	Cachexia, maldigestion if EPI develops
Vomiting	50%	Secondary pancreatitis, gastric compression, intestinal involvement
Abdominal Pain	Common	Tumor growth, pancreatitis, local invasion
Diarrhea	Variable	Maldigestion, EPI if tumor replaces functional tissue
Jaundice	Less common	Biliary obstruction by tumor in pancreatic head
Ascites	Variable	Carcinomatosis, hypoproteinemia
Lethargy/Depression	Common	Systemic illness, cancer cachexia

Clinical Signs and Presentation

Clinical signs are NONSPECIFIC, which is a major reason for late diagnosis. Most dogs present with vague gastrointestinal signs that mimic many other conditions, including pancreatitis. The tumor often remains subclinical until advanced or metastatic.

Common Clinical Signs

High-YieldJaundice is RARE in dogs with pancreatic adenocarcinoma compared to humans. When present, it indicates tumor location in the pancreatic head causing common bile duct obstruction. This is an important distinguishing feature.

Rare but Specific: Exocrine Pancreatic Insufficiency (EPI)

In rare cases, a large pancreatic adenocarcinoma can cause secondary EPI by destroying or replacing enough functional exocrine tissue. Clinical signs of EPI include chronic diarrhea, polyphagia, weight loss, and coprophagia. This is more commonly seen with diffuse disease or very large tumors.

Parameter	Finding
Canine Pancreatic Lipase (cPLI/Spec cPL)	May be elevated (secondary pancreatitis); can be NORMAL in ductal carcinomas
DGGR Lipase	May be elevated
Liver Enzymes (ALT, ALP)	Often elevated due to hepatic metastasis or biliary obstruction
Amylase	May be elevated (less specific than lipase)
C-Reactive Protein (CRP)	Elevated (inflammatory marker)
CBC	Inflammatory leukogram (neutrophilia, left shift possible)
Bilirubin	Elevated if biliary obstruction present

Diagnosis

Diagnosis of exocrine pancreatic tumors is challenging due to nonspecific clinical signs and the difficulty in differentiating neoplasia from pancreatitis on imaging. A definitive diagnosis requires cytologic or histopathologic examination.

Laboratory Findings

Laboratory abnormalities are nonspecific and often reflect secondary pancreatitis or metastatic disease:

NAVLE TipConcurrent pancreatitis is a COMMON histological finding alongside pancreatic carcinoma. In one study, 14/22 dogs (64%) with pancreatic carcinoma had concurrent mild-to-severe pancreatitis. This inflammation can MASK the underlying neoplasm and make cytologic diagnosis difficult.

Diagnostic Imaging

Radiography

Radiography has low sensitivity (approximately 19%) for detecting pancreatic neoplasia. Findings are nonspecific and may include loss of serosal detail in the right cranial abdomen, widening of the pyloro-duodenal angle, and cranial displacement of the transverse colon. Thoracic radiographs should be performed for metastasis screening.

Abdominal Ultrasonography

Ultrasound is the most widely available and commonly used modality for evaluating pancreatic disease, with a sensitivity of approximately 75% for detecting pancreatic neoplasia. However, differentiating neoplasia from pancreatitis can be challenging.

Computed Tomography (CT)

CT provides superior anatomical detail and is valuable for surgical planning and staging. Typical CT features of exocrine pancreatic carcinomas include:

Well-defined mass in 93% of cases
Heterogeneous contrast enhancement (73%)
Non-enhancing necrotic center common (40%)
Peripancreatic fat stranding (57%)
Lymphadenopathy (57%)
Extrahepatic biliary duct dilation if in right lobe

Cytology and Histopathology

Definitive diagnosis requires tissue examination. Fine-needle aspiration (FNA) can be performed under ultrasound guidance, but has limitations:

Cytology has high accuracy for acinar adenocarcinomas
Ductal adenocarcinomas are more difficult to diagnose on FNA
Concurrent pancreatitis can obscure neoplastic cells
Surgical biopsy (exploratory celiotomy or laparoscopy) may be required for definitive diagnosis

Histopathological Features

Ultrasound Finding	Interpretation
Hypoechoic mass	Most common appearance for adenocarcinoma
Hypovascular lesion (on CEUS)	Adenocarcinomas are typically hypovascular (vs. insulinomas which are hypervascular)
Irregular margins	Suggests malignancy and local invasion
Dilated common bile duct	If tumor in pancreatic head causing obstruction
Hepatic nodules	Metastatic disease
Lymphadenopathy	Regional lymph node metastasis (splenic, hepatic nodes)
Hyperechoic peripancreatic fat	Fat stranding - indicates inflammation or tumor extension

Treatment

Treatment options are limited and the prognosis is grave. The majority of dogs have metastatic disease at diagnosis, which precludes curative intent. Treatment is often palliative or supportive.

Surgical Treatment

Surgery offers the best chance for prolonged survival in dogs without metastatic disease, but clean surgical margins are rarely achieved. Surgical options include:

High-YieldPost-operative pancreatitis is a potentially life-threatening complication of any pancreatic surgery. Owners must be counseled about this risk. Close monitoring of pancreatic enzymes, hydration status, and pain management is essential post-operatively.

Medical Treatment

Exam Focus: The longest reported survival in a dog with exocrine pancreatic adenocarcinoma was 445 days with COMBINATION therapy: surgical resection (partial pancreatectomy) + toceranib phosphate + firocoxib. This represents an important case demonstrating that multimodal therapy may improve outcomes in carefully selected cases without metastatic disease.

Tumor Type	Histological Features
Acinar Adenocarcinoma	Highly cellular with minimal fibrous stroma. Cells with granular eosinophilic cytoplasm containing PAS-positive zymogen granules. Growth patterns: solid (most common), acinar, trabecular, clear cell, or mucinous. Positive for trypsin, chymotrypsin, BCL10.
Ductal Adenocarcinoma	Glandular growth pattern with prominent desmoplastic fibrous stroma. Mucin production (Alcian blue positive). Positive for CK7, CK19, MUC1. May have loss of SMAD4/DPC4 expression.

Prognosis

The prognosis for canine exocrine pancreatic adenocarcinoma is GRAVE. Key prognostic factors include:

Board Tip - Why the Grave Prognosis? Remember "LATE": Late presentation (nonspecific signs), Already metastasized (78% at diagnosis), Treatment options limited, Early euthanasia common. The combination of late diagnosis and high metastatic rate makes this one of the most challenging oncologic conditions in veterinary medicine.

Procedure	Indications and Considerations
Partial Pancreatectomy	Most commonly performed. Canine pancreas has significant regenerative capacity. Up to 75-90% can be resected if accessory pancreatic duct preserved. Appropriate for tumors in left lobe or distal right lobe.
Pancreaticoduodenectomy (Whipple procedure)	Indicated if accessory pancreatic duct involved. Higher complication rate. Rarely performed in veterinary medicine due to technical difficulty and morbidity.
Palliative Surgery	Biliary diversion if obstructive jaundice present. Gastrojejunostomy if gastric outflow obstruction. Biopsy only if complete resection not possible.

Differential Diagnosis

When evaluating a dog with a pancreatic mass or signs suggestive of pancreatic disease, consider:

Pancreatitis (acute or chronic) - most common differential; imaging and cytology often overlap
Pancreatic abscess - typically develops as complication of severe pancreatitis
Pancreatic pseudocyst - fluid-filled structure, not a true tumor
Insulinoma (endocrine tumor) - causes hypoglycemia; small, hypervascular on imaging
Gastrinoma - causes GI ulceration (Zollinger-Ellison syndrome)
Nodular hyperplasia - benign, common in older animals; usually incidental
Metastatic disease to pancreas - from gastric carcinoma, lymphoma, or other primary tumors

Treatment	Drug/Protocol	Notes
Tyrosine Kinase Inhibitor	Toceranib phosphate (Palladia) 2.5-2.75 mg/kg PO every 48 hours	Targets VEGFR, PDGFR, KIT. Median survival 89.5 days with toceranib alone; up to 445 days reported with surgery plus toceranib
COX-2 Inhibitor	Firocoxib (Previcox) or other NSAIDs	May have synergistic effect with toceranib. Monitor for GI side effects
Traditional Chemotherapy	Gemcitabine-based protocols	Limited success in veterinary patients. No established standard protocol
Supportive Care	Anti-emetics, appetite stimulants, pain management, nutritional support	Essential for maintaining quality of life

Prognostic Factor	Impact
Metastatic disease at diagnosis	Present in approximately 78% of cases. Precludes surgical cure.
Median overall survival (all cases)	1-8 days (confounded by early euthanasia)
Median survival with toceranib alone	89.5 days (range 14-506 days)
Best reported survival	445 days (surgery + toceranib + firocoxib, no metastasis at diagnosis)
Common metastatic sites	Liver (most common), regional lymph nodes, mesentery, intestines, lungs
Histopathologic grade	Well-differentiated tumors may have better prognosis

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →